Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Uncontrolled Chronic Rhinosinusitis Without Nasal Polyps
CTR20220094Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in chronic rhinosinusitis (CRS) (4 arms), sponsored by Sanofi. Primary endpoints: Change in sinus opacification at Week 24 (Lund-Mackay score, CT) and Change in total sinus symptom score (sTSS) at Week 24. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on CTR20220094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220094.